DDRGK1 and metabolic dysfunction-associated steatotic liver disease: Our findings suggest that ufmylation on UFBP1 alleviates NAFLD-related symptoms, including obesity, hepatic steatosis, insulin resistance, dyslipidemia and liver damage (Figs. 3–5).